Merck & Cohas reported a surge in third quarter net income, based on strong sales of key drugs, including Januvia, Janumet and Gardasil.

Diabetes medications Januvia and Janumet reported sales increases of 41% and 42% respectively over the corresponding 2010 results, amounting to sales figures of $846m and $350m.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Sales of Singulair, Merck’s leading asthma/allergic rhinitis treatment, rose 10% to $1.34bn, and it remains the company’s best-selling drug.

Company sales reached $12.02bn, representing an 8% increase, owing to a 5% boost from foreign exchange.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact